The Syncona Investment Trust

The investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science

Leave a Reply

Your email address will not be published. Required fields are marked *